Institute of Pharmaceutics, College of Pharmaceutical Sciences , Zhejiang University , Hangzhou 310058 , PR China.
Department of Pharmacy , The Fourth Affiliated Hospital, Zhejiang University School of Medicine , Yiwu 322000 , PR China.
ACS Appl Mater Interfaces. 2018 Sep 26;10(38):31903-31914. doi: 10.1021/acsami.8b09498. Epub 2018 Sep 17.
Both targeted and stimuli-sensitive drug-delivery systems (DDSs) have been developed to augment antitumor effects. However, lack of knowledge regarding tumor tissue targeting and different effects of the stimuli-sensitive DDSs in orthotropic and ectopic tumors have impeded further advances in their clinical applications. Herein, we first reported a pH-triggered micelle with sialic acid (SA)-driven targeting ability (SA-poly(ethylene glycol)-hydrazone linker-doxorubicin (DOX), SPD). The SPD micelles encapsulated with DOX (SPDD) showed sustained drug release over 48 h in response to the pH gradient in vivo, slow under physical conditions and accelerated in the acid tumor microenvironment. In addition, the SPD micelles showed 2.3-fold higher accumulation in tumors after 48 h compared to the micelles lacking the SA moiety. The overexpression of E-selectin on the inflammatory vascular endothelial cells surrounding the tumors increased the accumulation of SPD micelles in tumor tissues, whereas that on the tumor cells increased the internalization of micelles. Consequently, SPDD micelles exerted remarkable antitumor effects in both orthotopic and ectopic models. Application of SPDD micelles in the in situ model reduced the tumor volume (77.57 mm vs 62.13 mm) and metastasis after treatment for 25 days. These results suggest that SA-driven targeted DDS with a pH-responsive switch has the potential to treat hepatocarcinoma effectively both ectopically and orthotopically.
靶向和刺激敏感型药物递送系统(DDS)已被开发用于增强抗肿瘤效果。然而,由于对肿瘤组织靶向性的认识不足以及刺激敏感型 DDS 在原位和异位肿瘤中的不同作用,其临床应用进一步发展受到了阻碍。在这里,我们首次报道了一种具有唾液酸(SA)驱动靶向能力的 pH 触发胶束(SA-聚乙二醇-腙链接物-阿霉素(DOX),SPD)。SPD 胶束包载 DOX(SPDD)在体内 pH 梯度下可持续释放药物超过 48 小时,在物理条件下释放缓慢,在酸性肿瘤微环境中加速释放。此外,与缺乏 SA 部分的胶束相比,SPD 胶束在 48 小时后在肿瘤中的积累增加了 2.3 倍。肿瘤周围炎症性血管内皮细胞中 E-选择素的过表达增加了 SPD 胶束在肿瘤组织中的积累,而肿瘤细胞上的 E-选择素则增加了胶束的内化。因此,SPDD 胶束在原位和异位模型中均表现出显著的抗肿瘤效果。在原位模型中应用 SPDD 胶束治疗 25 天后,肿瘤体积(77.57mm 对 62.13mm)和转移得到显著减少。这些结果表明,具有 pH 响应开关的 SA 驱动靶向 DDS 有可能有效地异位和原位治疗肝癌。